FDA 483 - GlaxoSmithKline Biologicals Kft. - January 31, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of GlaxoSmithKline Biologicals Kft. in Godollo, Hungary, a licensed biological drug manufacturer, revealed significant deficiencies in manufacturing investigations and material acceptance procedures. The firm failed to adequately investigate particulate contamination and temperature excursions, leading to the release of potentially compromised vaccine batches. Additionally, procedures for accepting components with particulate matter were found to be inadequate, lacking proper risk assessments.
ID · ea27ad0a-a637-4b0d-a339-8b06f7455608